Navigation Links
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Date:5/29/2009

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor

NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor," was presented earlier today in a poster session at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Orlando, Florida. Later this afternoon, the data will also be presented by Dr. Brian Rini, Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, in a poster discussion during the Genitourinary Cancer session.

The study enrolled a total of 50 patients, of which 46 patients were evaluable for response. Evaluable patients were defined as those who had greater than 7 days of treatment. The primary endpoint of this study was clinical benefit, defined as response rate (RECIST), and progression-free survival (PFS) in RCC patients who failed a prior VEGF receptor inhibitor (sunitinib or sorafenib). Safety of perifosine in this patient population was evaluated as a secondary endpoint. Best response to single agent perifosine was as follows:

      Group     N       PR      SD > 12 wks    CBR*       Median PFS
                       N (%)       N (%)       N (%)       (SD or >)
     All Pts    46    5 (11%)    16 (35%)    21 (46%)      33 weeks
                                                      [95% CI (24, 
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
6. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
7. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
11. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  World-renowned prostate surgeon and New York Urologist, Dr. ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate ... at Lenox Hill Hospital is the only center using ... New York City . We,ve seen tremendous improvement in ... use of an MRI makes for a much more accurate ...
(Date:5/28/2015)... and HOUSTON , May 28, ... (TSX-V: EPI) today reported financial results for the second quarter ... unless specified otherwise, are expressed in Canadian dollars and in ... Summary Results ESSA recorded a net loss ... months ended March 31, 2015 (Q2-2015), compared to a net ...
(Date:5/28/2015)... N.Y. , May 28, 2015 ... the world,s largest provider of health care products ... medical practitioners, today reminded its customers that the ... dentists, physicians and veterinarians who experience operational, logistical ... disastrous storms in the South Central region of ...
Breaking Medicine Technology:MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 2Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Storms In South Central, U.S. 3
... NicOx S.A.,(Euronext Paris: COX) today announced it ... (OA) patients with controlled hypertension,in two clinical ... line with,previously announced timelines. These trials are ... naproxcinod, in comparison to ibuprofen and,naproxen, using ...
... Ari Kiev, M.D., president of SPRI,Clinical Trials, will be ... The Trout Group Investor Seminar -- Management,s Guide to,Wall ... 30, at Midtown,Loft & Terrace, 267 Fifth Avenue in ... at private and small and mid-cap life science companies ...
Cached Medicine Technology:NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... 29, 2015 OncLive proudly announces the ... medical pioneers recognized by a panel of eminent oncologists ... cancer treatment. Honorees will be introduced and celebrated TONIGHT ... Ceremony, held 8:30-11:00 p.m. CDT at The Chicago Illuminating ... are being recognized for groundbreaking accomplishments, in fields including ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
(Date:5/29/2015)... 29, 2015 Dr. Rodger Murphree, ... Fatigue Syndrome is now offering free weekly call ... about natural ways to reduce symptoms associated with ... sleep, and brain fog. , To find ... Beating Fibromyalgia call in teleconferences simply go to ...
(Date:5/29/2015)... Healthpointe clinics throughout Southern California are now ... their licensed clinical psychologist, Dr. Levon Margolin. Despite ... an extensive array of physical, cognitive, emotional, and behavioral ... time after a traumatic ordeal involving the brain. Traumatic ... jolt to the head that impedes the normal function ...
Breaking Medicine News(10 mins):Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Healthpointe’s Los Angeles County Clinics Are Now Offering Treatment for Mild Traumatic Brain Injuries 2
... World,s Largest AIDS Fundraising Event Attracts 45,000 Participants and ... Raises Record Sum., Results Defy Economic Downturn and Remind Policy ... ... Walk,New York, on Sunday May 18, was the largest and most successful AIDS Walk,ever held, ...
... avoids incisions, shortens recoveries , , SUNDAY, May 18 ... lead to painless and scar-free surgery with recovery ... surgery, U.S. studies suggest. , Called natural ... inserted through a natural body opening, rather than ...
... ERs sicker than women, more likely to die within a ... into emergency departments with pneumonia are likely to be sicker ... risk of dying within a year, despite receiving more aggressive ... on research from the University of Pittsburgh, were scheduled to ...
... May 18, 2008 Researchers at Washington University School ... type of immune response that is activated in patients ... Their discovery could dramatically improve diagnosis and treatment of ... first part of the molecular code that links a ...
... One ... Family, Disease Hard to ... Work; No Studies on Long-Term Effects in Children, NEW YORK, May 18 ... Up Bipolar" (on newsstands,Monday, May 19), childhood bipolar disorder is hard to pin ...
... ATS 2008, TORONTOWomen who are stressed during pregnancy may ... the form of increased sensitivity to allergen exposure and ... Medical School who will present their findings at the ... Sunday, May 18. , While predisposition to asthma ...
Cached Medicine News:Health News:AIDS Walk New York Raises $7.05 Million 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 3Health News:Study Finds Gender Disparity in Community-Acquired Pneumonia 2Health News:Personalized therapy for asthma and COPD could soon be here 2Health News:Personalized therapy for asthma and COPD could soon be here 3Health News:Personalized therapy for asthma and COPD could soon be here 4Health News:NEWSWEEK Cover: Growing Up Bipolar 2Health News:NEWSWEEK Cover: Growing Up Bipolar 3Health News:Mother's prenatal stress predisposes their babies to asthma and allergy 2
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... a low implant profile, 0.84mm, for better ... insertion is technically simpler and allows a ... installed with less trauma than multiple quadrant ... implant were designed to minimize bleb height ...
1-Meter Roll-Up Tangent Screen....
... accurate detections of any ... as glaucoma in the ... performed. Smooth operation of ... High accuracy of static ...
Medicine Products: